12:39 PM EDT, 10/20/2025 (MT Newswires) -- Celcuity ( CELC ) shares rose more than 42% in recent Monday trading after the company reported phase 3 data showing its experimental drug gedatolisib significantly improved progression-free survival in patients with advanced breast cancer.

The company said the trial was conducted in patients with the PIK3CA wild-type gene, hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer who were treated with a CDK4/6 inhibitor and an aromatase inhibitor.

Patients in the trial treated with gedatolisib, palbociclib, and fulvestrant, also known as the gedatolisib triplet, exhibited a median progression-free survival of 9.3 months compared with 2.0 months for those given fulvestrant alone, the company said.

Patients treated with gedatolisib and fulvestrant showed median progression-free survival of 7.4 months versus 2.0 months with fulvestrant.

Hyperglycemia was reported in 9.2% of patients in the triplet group and 11.5% in the doublet arm, according to the statement.

Price: 74.02, Change: +22.06, Percent Change: +42.46